CHF42.54 close BMY.SW Bristol-Myers Squibb (SIX) 18 Feb 2026: oversold bounce

BMY.SW stock closed at CHF42.54 on 18 Feb 2026, down 4.40% as the session ended. The move left shares below the 50-day average CHF43.75 and created a short-term oversold profile. Volume was light at 500.00 shares but relative volume spiked to 22.73, suggesting rapid order flow. We view today as an oversold bounce opportunity, not a trend reversal, and focus on catalysts, technical triggers, and risk controls for short trades or cautious buys.

Price action and session summary for BMY.SW stock

BMY.SW stock closed at CHF42.54, down CHF1.96 or -4.40% from a previous close of CHF44.50. The session showed a single-price print with day high and low at CHF42.54 and year high at CHF44.75.

Market cap stood near CHF70,703,584,454.00 (CHF70.70B) and trading volume was 500.00 versus average volume 22.00, producing a relative volume of 22.73. The price sits just under the 50-day and 200-day averages of CHF43.75, an important level for mean-reversion plays.

News, fundamentals and why the drop matters

Newsflow around juvenile idiopathic arthritis and the roll-out of SOTYKTU is in focus. SOTYKTU, developed by Bristol-Myers Squibb, is listed as an emerging therapy in market reports and may shift medium-term revenue mix source source.

On fundamentals, BMY reports EPS CHF2.69 and a trailing PE of 15.81. Free cash flow metrics are strong with a free cash flow yield of 23.47% in recent metrics, which supports dividends and buybacks. The headline drop likely reflected short-term positioning rather than a structural earnings shock.

BMY.SW stock technical setup and oversold bounce signals

Technical indicators show short-term oversold conditions. MACD is -0.11 with a signal at -0.04, and ADX reads 100.00, indicating a strong directional move that may be overextended. ATR is 0.15, keeping intraday risk tight.

Price is below the 50-day average CHF43.75 but close enough to allow a mean-reversion target near CHF44.00. A practical bounce trigger would be a reclaim of CHF43.75 on rising volume and a MACD cross. Stop-loss should sit beneath today’s low at CHF42.54 for short-term trades.

Meyka AI rates BMY.SW with a score out of 100 and valuation view

Meyka AI rates BMY.SW with a score out of 100: Score 73.30 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Valuation metrics show price to sales 1.30, price to book 4.52, and dividend yield around 3.50%. The company’s debt-to-equity is high at 3.45, which increases leverage risk but the interest coverage is 6.47, which supports near-term servicing.

Risks, catalysts and sector context for BMY.SW stock

Key risks include pipeline setbacks, regulatory delays for new indications, and high leverage that amplifies downside. The healthcare sector average PE is 34.15, making Bristol-Myers’ PE 15.81 relatively cheap on earnings but debt-exposed.

Near-term catalysts that could support a bounce are positive trial readouts, label expansions, and clearer uptake for SOTYKTU in juvenile indications. Watch sector momentum; healthcare has returned 11.34% over three months in local benchmarks, which could lift BMY.SW if sentiment improves.

Practical trade plan and positioning for an oversold bounce

For traders, a tested entry is on a volume-backed reclaim of CHF43.75, with a short target at CHF44.00 and a stretch target of CHF46.00. Risk per trade should be capped to a preset percentage, using a stop under CHF42.54.

For investors using an oversold-bounce strategy, scale in small lots. Monitor upcoming earnings, next announcement date 2026-04-30, and real-world uptake for SOTYKTU. Keep exposure modest until leverage and pipeline visibility improve.

Final Thoughts

BMY.SW stock closed at CHF42.54 on 18 Feb 2026 after a -4.40% move that created a short-term oversold setup. Technicals point to a possible rebound toward the 50-day average CHF43.75, with an immediate bounce target of CHF44.00 (implied upside 3.43%) and a medium target near CHF46.00 (implied upside 8.13%). Meyka AI’s forecast model projects a one-year model price of CHF39.34, implying a -7.52% downside versus today. Meyka AI’s forecast model projects this figure and it is model-based projection, not a guarantee. Use tight stops under CHF42.54 and treat any buy as a mean-reversion trade, not a full conviction long. Monitor SOTYKTU adoption and upcoming earnings which will drive the next price leg. Meyka AI-powered market analysis supports a cautious, size-controlled oversold bounce approach given solid cash flow but elevated leverage.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.